73-LB: Ambulatory Glucose Profile Informs Better Treatment Decisions for Type 2 Basal-Insulin Patients

Abstract

Healthcare providers (HCP) treating patients who are on basal insulin and have suboptimal glycemic control may benefit from understanding glucose patterns. The primary objective of this study is to evaluate whether a review of Ambulatory Glucose Profile (AGP) of the patient would enable the HCP to recommend a therapy change. The secondary objectives included evaluating HCPs’ understanding of their patients’ glycemic control and patients’ understanding of the rationale for the recommended treatment after reviewing the AGP with their physician. A total of 136 patients with HbA1c values of 7.0 - 10.0% for whom their HCP is unsure of the optimal course of treatment based on standard of care were enrolled in the study at 10 sites and used FreeStyle Libre Pro Sensors;105 patients had at least 7 days of sensor data to generate an AGP. All HCPs received training on AGP interpretation. Based on their AGP, 94.3% (99/105) of the patients were recommended a therapy change. In addition, HCPs found that sensor data were useful in understanding their patients’ glycemic control, provided new insights on overall glucose control, and helped to make better informed treatment decisions for their patients (Table 1) . Patients also had a better understanding of the recommended treatment after reviewing the AGP with their HCP, where 96.7% of the patients understood the rationale of their recommended treatment. Disclosure E. Huang: Employee; Abbott Diabetes. M. Nada: Employee; Abbott Diabetes. E. Wright: Advisory Panel; Abbott Diabetes, Bayer AG, Boehringer Ingelheim International GmbH, Gelesis, GlaxoSmithKline plc., Lilly Diabetes, MannKind Corporation, Medtronic, Sanofi-Aventis U. S., Consultant; Abbott Diabetes, Bayer AG, Bigfoot Biomedical, Inc., Boehringer Ingelheim International GmbH, Lilly Diabetes, Stability Health, Other Relationship; UpToDate, Speaker's Bureau; Abbott Diabetes, American Diabetes Association, Bayer AG, Boehringer Ingelheim International GmbH, Sanofi-Aventis U. S. Funding Abbott Diabetes Care